Definium Therapeutics (NASDAQ:DFTX) Given New $60.00 Price Target at Stifel Nicolaus

Definium Therapeutics (NASDAQ:DFTX) had its price target boosted by Stifel Nicolaus from $30.00 to $60.00 in a research note published on Wednesday, Marketbeat reports. The brokerage currently has a buy rating on the stock.

Several other brokerages also recently commented on DFTX. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Leerink Partners set a $52.00 target price on Definium Therapeutics and gave the company an “outperform” rating in a research report on Monday, June 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Tuesday, April 21st. Needham & Company LLC upped their price target on shares of Definium Therapeutics from $38.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, June 23rd. Finally, Wall Street Zen raised shares of Definium Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, July 4th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $49.23.

Definium Therapeutics Stock Performance

Shares of DFTX stock opened at $45.32 on Wednesday. The firm has a market cap of $4.52 billion, a PE ratio of -18.20 and a beta of 2.20. The company’s fifty day simple moving average is $28.14 and its 200-day simple moving average is $21.24. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.15. Definium Therapeutics has a 12 month low of $7.54 and a 12 month high of $49.20.

Definium Therapeutics (NASDAQ:DFTX) last issued its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.23). Equities research analysts expect that Definium Therapeutics will post -2.29 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Brandi Roberts sold 3,013 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $135,675.39. Following the completion of the sale, the chief financial officer owned 209,487 shares of the company’s stock, valued at $9,433,199.61. This represents a 1.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Matthew T. Wiley sold 2,867 shares of Definium Therapeutics stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $129,101.01. Following the completion of the transaction, the insider directly owned 174,633 shares in the company, valued at $7,863,723.99. This trade represents a 1.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 48,096 shares of company stock worth $2,165,763 in the last ninety days. 2.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Royal Bank of Canada raised its position in Definium Therapeutics by 10.4% in the first quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock valued at $382,000 after purchasing an additional 6,148 shares during the last quarter. Creative Planning boosted its position in Definium Therapeutics by 2.6% during the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock worth $429,000 after buying an additional 1,655 shares during the period. JPMorgan Chase & Co. boosted its position in Definium Therapeutics by 5.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company’s stock worth $315,000 after buying an additional 2,342 shares during the period. Rhumbline Advisers grew its holdings in Definium Therapeutics by 6.3% during the 2nd quarter. Rhumbline Advisers now owns 115,296 shares of the company’s stock worth $748,000 after acquiring an additional 6,839 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after acquiring an additional 2,003 shares during the last quarter. 27.91% of the stock is currently owned by institutional investors.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.